



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/769,404	01/26/2001	Theo Wallimann	8932-296	4809
20582	7590	03/13/2008		
JONES DAY 222 East 41st Street New York, NY 10017-6702			EXAMINER WANG, SHENGJUN	
			ART UNIT	PAPER NUMBER
			1617	
			MAIL DATE	DELIVERY MODE
			03/13/2008 PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/769,404

Applicant(s)

WALLIMANN ET AL.

Examiner

Shengjun Wang

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 23, 24 and 31-41 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 23, 24 and 31-41 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date: ____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date: ____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____

DETAILED ACTION

Receipt of applicants' remarks submitted December 13, 2007 is acknowledged.

Claim Rejections 35 U.S.C. 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 23, 24, 31-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaddurah-Daouk (US 5,998,457) in view of Meisner (US 4,772,591), Grant et al. (US 5,888,553), Beale (US 5,756,469) and Beale (US 5,716,926).
3. Kaddurah-Daouk teaches a method of treating osteoporosis or osteoarthritis comprising administering therapeutical effective amount of creatine compound, or a pharmaceutical acceptable salt, to patient. See, particularly, the abstract, table 1-2, and claims 1-12. As to the amount of creatine administered, Kaddurah-Daouk states: "the actual amount of drug needed will be depend on factors such as the size, age, and severity of disease in afflicted individual. ... for this invention the creatine compound will be administered at dosage and period of time effective to reduce, ameliorate or eliminate the symptoms of the disease." Col. 11, lines 24-44.
4. Kaddurah-Daouk does not teach expressly the employment of creatine pyruvate for the treatment, or the particular amount administered, or the method may be employed for promoting growth and mineralization of bone; improving acceptance and osseous integration of bone; or accelerating healing as claimed herein.

5. However, Grant et al. teaches that the excess of cortisol is known to be a cause of osteoporosis, tissue degeneration, and an anabolic composition with anticortisol effect are used to balance effect of cortisol. The anabolic composition comprising creatine or its salts, wherein the amount of creatine or its salts is in the range of 1-10,000 mg. See, column 1, line 52 bridging column 2, line 59, column 5, lines 56-65, column 13, lines 8-9, and claim 8. Meisner teaches a method for accelerated wound healing or treating degenerative disorders including periodontal disease, osteoarthritis, comprising administering a composition comprising creatine to an animal or human. See, particularly, column 1, line 28 bridging column 2, line 45, column 5, lines 3 bridging column 7, line 10. Beale ('469) teaches creatine pyruvate (pyruvyl-creatine) is particularly useful as cortisol antagonist or cortisol blocker for prevent the catabolic activity of cortisol. See column 1, lines 7-18, 54-60; column 3, lines 46-63, and column 5, lines 54-60. Beale ('926) further teaches that pyruvate is known to be useful for treating osteoporosis. See, claim 24.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise. Note claims 23 and 24 read on the composition comprising creatine pyruvate, since creatine pyruvate is both a creatine salt, and a pyruvate.

A person of ordinary skill in the art would have been motivated to employ creatine pyruvate composition, for improving bone conditions, or for accelerating healing of pathogenic bone conditions, including bone implantation and defect bone caused by trauma or otherwise.

because creatine and pyruvate, either alone, or in combinations are known to be useful for improving bone conditions. Further, it is prima facie obvious to combine two compounds each of which is taught in the prior art to be useful for same purpose in order to form third composition that is to be used for very the same purpose; idea of combining them flows logically from their having been individually taught in prior art; thus, the claimed invention which employ a combination (salt) of two compounds known to be useful for treating osteoporosis sets forth prima facie obvious subject matter. See In re Kerkhoven, 205 USPQ 1069. Note treating osteoporosis is to promoting mineralization of bone. Further, creatine pyruvate is particularly known to be useful for treating disease associated with cortisol activity and connective tissue degenerative disorders is known to be closely related to cortisol activity. Finally, creatine is known to be useful for promoting tissue repair process, and treating osteoarthritis and osteoporosis would also considered as a process of promoting tissue (cartilage) repairing since one of the major symptoms of osteoarthritis and osteoporosis is tissue degeneration. Finally, The optimization of a result effective parameter, e.g., the effective amount of creatine, particularly within the range of the prior art, is considered within the skill of the artisan, absent evidence to the contrary. See, In re Boesch and Slaney (CCPA) 204 USPQ 215. Furthermore, the instant claims are essentially directed to a particular salt of creatine for treating disorders known to be treated by creatine, or its derivatives, or its salts. Absent evidence to the contrary, the employment of pyruvate creatine is seen to be a selection from amongst equally suitable material and as such obvious. Ex parte Winters 11 USPQ 2nd 1387 (at 1388). It is well settled that in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima

facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed.Cir. 1990).

Response to the Arguments

Applicants' amendments and remarks submitted April 17, 2007 have been fully considered, but are not persuasive.

6. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Particularly, the cited references as a whole teach that creatine and pyruvate are useful for treatment of various bone diseases, from degenerative disease to wound healing process. Possessing such knowledge, one of ordinary skill in the art would have been motivated to use creatine pyruvate for promoting the healing process of damaged bone.

Applicants contend that the references do not teach all the limitation recited in the claims. Specifically, "to a *subject having a bone implant*, as recited in claim 23, or a *subject having a defect in bone tissue caused by trauma or surgery*, as recited in claims 24 and 37." The examiner respectfully disagrees.

7. Meisner teaches a method for accelerated wound healing or treating degenerative disorders including periodontal disease, osteoarthritis, comprising administering a composition comprising creatine to an animal or human. See, particularly, column 1, line 28 bridging column

2, line 45, column 5, lines 3 bridging column 7, line 10. It would have been obvious to one of ordinary skill in the art to employ creatine for promoting the healing process for defected bone. Applicants also argue the claims herein are not obvious over the cited references as “the references are directed to different class of substance having different biochemical properties and for treating different diseases.” The arguments are unpersuasive. The cited references may teach other compounds with different properties, nevertheless, the cited references teach the usefulness for treating bone abnormality. Note question under 35 U.S.C. 103 is not merely what reference expressly teach, but what they would have suggested to one of ordinary skill in the art at the time the invention was made; all disclosures of prior art, including unpreferred embodiments, must be considered. In re Lamberti and Konort (CCPA), 192 USPQ 278.

8. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., without the employment of other active ingredients as cited in the references) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

9. In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir.

1992). In this case, the teaching, suggestion and motivation are found in the cited references and in the knowledge generally available to one of ordinary skill in the art.

Applicants' assertion that "Kaddurah-Dauok is complete for their intended purposes and, thus, a person of ordinary skill in the art would have no motivation to use a secondary reference ..." are untenable. Applicants' attention is directed to KSR vs. Teleflex, where the court states: "When there is a design need or market pressure to solve a problem and there are a finite number of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense." In the instant case, one of ordinary skill in the art would have motivated to pursue the known option within his grasp for treatment of bone defects.

10. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Shengjun Wang/
Primary Examiner, Art Unit 1617